Last reviewed · How we verify
(vic-)trastuzumab duocarmazine
Trastuzumab duocarmazine is an antibody-drug conjugate that binds HER2-positive cancer cells and delivers a DNA-damaging payload intracellularly.
Trastuzumab duocarmazine is an antibody-drug conjugate that binds HER2-positive cancer cells and delivers a DNA-damaging payload intracellularly. Used for HER2-positive breast cancer, HER2-positive gastric cancer.
At a glance
| Generic name | (vic-)trastuzumab duocarmazine |
|---|---|
| Also known as | SYD985, Trastuzumab vc-seco-DUBA |
| Sponsor | Byondis B.V. |
| Drug class | Antibody-drug conjugate (ADC) |
| Target | HER2 (human epidermal growth factor receptor 2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The drug combines trastuzumab (anti-HER2 monoclonal antibody) with duocarmycin, a potent DNA alkylating agent, via a cleavable linker. Upon binding to HER2 on cancer cells, the conjugate is internalized and the duocarmycin payload is released intracellularly, causing DNA damage and cell death. This targeted delivery mechanism aims to maximize efficacy while reducing systemic toxicity compared to unconjugated chemotherapy.
Approved indications
- HER2-positive breast cancer
- HER2-positive gastric cancer
Common side effects
- Nausea
- Fatigue
- Diarrhea
- Neutropenia
- Thrombocytopenia
Key clinical trials
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma (PHASE2)
- Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985 (PHASE1, PHASE2)
- Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors (PHASE1)
- ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer (PHASE1)
- SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- (vic-)trastuzumab duocarmazine CI brief — competitive landscape report
- (vic-)trastuzumab duocarmazine updates RSS · CI watch RSS
- Byondis B.V. portfolio CI